Valuation Boston Scientific Corporation
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.92 USD | +6.15% |
|
+4.78% | -41.35% |
Company Valuation: Boston Scientific Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 60,534 | 66,273 | 84,691 | 131,642 | 141,351 | 83,117 | - | - |
| Change | - | 9.48% | 27.79% | 55.44% | 7.37% | -41.2% | - | - |
| Enterprise Value (EV) 1 | 67,674 | 74,280 | 92,928 | 141,974 | 150,822 | 89,411 | 86,016 | 82,015 |
| Change | - | 9.76% | 25.1% | 52.78% | 6.23% | -40.72% | -3.8% | -4.65% |
| P/E ratio | 61.6x | 103x | 54x | 71.5x | 49.1x | 20.6x | 19.5x | 17.1x |
| PBR | 3.64x | 3.77x | 4.39x | 6.05x | 5.84x | 2.95x | 2.62x | 2.33x |
| PEG | - | -3x | 0x | 4.3x | 0.9x | 0.5x | 3.39x | 1.2x |
| Capitalization / Revenue | 5.09x | 5.23x | 5.95x | 7.86x | 7.04x | 3.83x | 3.53x | 3.25x |
| EV / Revenue | 5.69x | 5.86x | 6.53x | 8.48x | 7.51x | 4.12x | 3.65x | 3.2x |
| EV / EBITDA | 16.5x | 20.8x | 22.6x | 29.3x | 25.3x | 13.4x | 11.6x | 10x |
| EV / EBIT | 22.5x | 22.9x | 24.9x | 31.3x | 26.9x | 14.5x | 12.7x | 10.9x |
| EV / FCF | 51.4x | 79.2x | 51.9x | 53.7x | 41.2x | 21.3x | 20.4x | 15.4x |
| FCF Yield | 1.94% | 1.26% | 1.93% | 1.86% | 2.43% | 4.7% | 4.9% | 6.5% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.69 | 0.45 | 1.07 | 1.25 | 1.94 | 2.711 | 2.867 | 3.273 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 11,888 | 12,682 | 14,240 | 16,747 | 20,074 | 21,681 | 23,569 | 25,607 |
| EBITDA 1 | 4,103 | 3,574 | 4,106 | 4,839 | 5,973 | 6,683 | 7,394 | 8,199 |
| EBIT 1 | 3,010 | 3,241 | 3,738 | 4,529 | 5,612 | 6,173 | 6,795 | 7,526 |
| Net income 1 | 985 | 642 | 1,570 | 1,853 | 2,898 | 3,924 | 4,169 | 4,801 |
| Net Debt 1 | 7,140 | 8,007 | 8,237 | 10,332 | 9,471 | 6,294 | 2,899 | -1,102 |
| Reference price 2 | 42.48 | 46.27 | 57.81 | 89.32 | 95.35 | 55.92 | 55.92 | 55.92 |
| Nbr of stocks (in thousands) | 1,424,992 | 1,432,311 | 1,464,983 | 1,473,827 | 1,482,442 | 1,486,355 | - | - |
| Announcement Date | 2/2/22 | 2/1/23 | 1/31/24 | 2/5/25 | 2/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 20.63x | 4.12x | 13.38x | -.--% | 83.12B | ||
| 21.98x | 4.08x | 15.74x | 0.42% | 164B | ||
| 48.31x | 12.66x | 28.37x | -.--% | 156B | ||
| 25.98x | 4.91x | 15.3x | 0.91% | 116B | ||
| 29.38x | 6.54x | 20.7x | -.--% | 47.44B | ||
| 17.73x | 2.06x | 10.53x | 2.96% | 43.71B | ||
| 35.47x | 5.71x | 17.42x | -.--% | 32.62B | ||
| 21.5x | 4.41x | 15.29x | 0.91% | 31.68B | ||
| 19.27x | 5.08x | 12.78x | 1.19% | 29.61B | ||
| 21.86x | 4.7x | 14.65x | 2.87% | 27.77B | ||
| Average | 26.21x | 5.43x | 16.41x | 0.93% | 73.2B | |
| Weighted average by Cap. | 28.76x | 6.23x | 17.99x | 0.61% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- BSX Stock
- Valuation Boston Scientific Corporation
Select your edition
All financial news and data tailored to specific country editions
















